Plastic Prefilled Syringes: A Better Fit for Autoinjector Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Plastic Prefilled Syringes: A Better Fit for Autoinjector Systems
The authors describe the ways in which plastic prefilled syringes can be an alternative that provides consistent performance, protects drugs prone to degradation, and enhances patient safety.


Pharmaceutical Technology


Summary

Despite the fact that glass is still the predominant material, plastic prefilled syringes are gaining ground because of the many benefits associated with cyclic olefin polymer resins. Drug manufacturers that seek autoinjector technology for their products, particularly for biologicals and vaccines, should consult a vendor that understands primary container performance. Syringes' dimensions should be as consistent as possible, and the syringes should preferably be molded instead of formed, to help overcome the problem of break-force variability. Plastic syringes also can improve the safety of the delivery by eliminating tungsten or glue contamination. If a glass syringe is necessary, the autoinjector itself can be modified to aid the delivery process by registering the force on the strongest part of the syringe. This technique helps to overcome the dimensional variability of the glass prefilled syringe, reduce breakage, provide a consistent depth of injection, and create a reliable system that delivers the dose easily and effectively to the patient.

Douglas Stout* is director of strategic market development, and Vinod Vilivalam is director of strategic market and technical development for the Daikyo Crystal Zenith prefillable and vial platform, both at West, 101 Gordon Dr., Lionville, PA 19341, tel. 732.946.2929, fax 732.945.2189.

*To whom all correspondence should be addressed.

References

1. M.N. Eakins, Am. Pharm. Rev. 10 (6), 47–51 (2007).

2. B. Harrison and M. Rios, Pharm. Technol. 31 (3), 50–60 (2007).

3. B. Detournay et al., Eur. Hosp. Pharm. 4 (4), 109–113 (1998).

4. M.J. Akers et al., PDA J. Pharm. Sci. Technol. 61 (5), 337–361 (2007).

5. B. Eu et al., poster presented at AAPS National Biotechnology Conference, Toronto, June 2008.

6. MHRA, Class 2 Drug Alert, Medicines Recall, Reference MDR 03-10/06, Neulasta SureClick Injection Device (London, Oct. 4, 2006).

7. R. Esfandairy et al., poster presented at AAPS National Biotechnology Conference, Toronto, June 2008.

8. B. Lahendro, http://OnDrugDelivery.com/, http://www.ondrugdelivery.com/publications/prefilled_syringes_2008.pdf (2008), accessed Oct. 19, 2009.

9. J. Shin et al., Pure Appl. Chem. 77 (5), 801–814 (2005).

10. M.N. Eakins, Bioprocess Int. 3 (6), 52–58 (2005).

11. J.S. Bee et al., J. Pharm. Sci. 98 (9), 3290–3301 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
8%
All of the above.
45%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here